Summary
Various studies revealed that elevated expression of CD97 in carcinomas is associated with the dedifferentiation, aggressiveness and metastasis of tumour. CD97 is a protein member of the epidermal growth factor seven-transmembrane (EGF-TM7) family of class II TM7 receptors. Our previous study suggested that the overexpression of CD97 in cervical cancer was correlated with the aggressiveness of the tumour and that CD97 might be an independent poor prognostic factor for cervical cancer patients. Based on these data, we have investigated the role of CD97 small isoform in cervical cancer proliferation, migration and invasion in vitro. Three cervical cancer cell lines were tested and the CD97 small isoform was found to be expressed predominantly in the SiHa cells. The mobile and invasive ability of different cervical cancer cell lines was not correlated positively with total CD97 protein expression but was with the level of the CD97 small isoform. Functional significance was assessed 48 hours after transient knockdown using siRNA targeting CD97 small isoform (CD97/EGF1,2,5) or a scrambled control sequence in cervical cancer cell lines. As a result, decreased ability of migration and invasion was found in CD97 small isoform RNAi cells, which showed, however, no change in cell proliferation. This study shed light on the role of the CD97 small isoform in tumour progression and provides a basis for further studies to determine its function in vivo.
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migration and invasion by cervical cancer is still scanty. In this study, therefore, we investigated the role of CD97 small isoform in cervical cancer further in vitro by using cells which had undergone CD97 small isoform silencing.
| MATERIALS AND METHODS

| Cell lines
All cell lines used in this study were purchased from Chinese Academy of Sciences Cell Bank, and cervical cancer cell line HeLa (HPV18+), SiHa (HPV16+) and C33A (HPV-) were cultured in RPMI-1640. All media were supplemented with 10% foetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin. The cells were grown in a standard humidified incubator in 5% CO 2 at 37°C and passaged every 3-4 days using trypsin-EDTA.
| Knockdown of CD97 small isoform by small interfering RNA (siRNA)
Four RNAi candidate target sequences of human CD97 small isoform (CD97/EGF1,2,5) were designed ( Table 1) . The cervical cancer cells (HeLa, SiHa) were transfected with 100 nmol/L of the optimal target siRNA sequence (9252) in serum-free Opti-MEM medium with the use of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as suggested by the manufacturer's instructions. Scrambled siRNA was used as a control. Expression of CD97 isoforms was verified by RT-PCR, and the total CD97 protein expression was tested by Western blot analysis.
| Total RNA Extraction and Reverse
Transcriptase Polymerase Chain Reaction (RT-PCR)
Total cell RNA was isolated using RNeasy mini kit (Qiagen). Reverse transcription polymerase chain reaction (RT-PCR) was performed using the Qiagen OneStep RT-PCR Kit. Total RNA 1 μg served as template for each reaction. RT was performed at 50°C for 30 minutes. Primers were designed for amplification of all three CD97 isoforms (sense: TCAGAACTCCTCGTGTGTCAATG; antisense: CGAAGAATCGGGAAAGCGT). For PCR, 35 cycles were used at 94°C for 30 seconds, 61°C for 45 seconds and 72°C for 60 seconds. The RT-PCR products were visualized on 1% agarose gel using ethidium bromide. β-Actin (sense: TTCCAGCCTTCCTTCCTGGG; antisense: TTGCGCTCAGGAGGAGCAAT) cDNA was served as an internal control.
| Western blot analysis
CD97 protein expression was analysed by Western blot analysis. Western blot analysis was performed according to a standard protocol. 13 Rabbit anti-human CD97 polyclonal antibody (NBP2-24552) was obtained from NOVUS Biotechnology. The horseradish peroxidase (HRP)-conjugated rabbit anti-goat IgG was obtained from DakoCytomation. The signal of each band was quantified with Image-Pro Plus 4.5 software. All results were normalized to GADPH.
| Invasion and migration assay
The invasion assay was evaluated in 24-well Matrigel TM transwell chambers (BD). Cells were seeded at 6 × 10 4 cells/well (200 μL) in RPMI-1640 medium with 1% FBS in the upper chamber and the lower chamber was filled with 600 μl RPMI-1640 medium with 10% FBS. After 24-hours incubation in a 5% CO 2 atmosphere at 37°C, cells remaining on top of the filter were wiped off with swab stick. Invasion chambers were fixed in methanol for 15 minutes, stained with 0.1% Toluidine blue (Sigma) in 2.5% sodium carbonate and washed in chilled PBS. Invaded cells were counted by light microscopy in four different high-power fields per filter. For the migration assay, we used transwell chambers (Corning).
| Statistical analysis
Statistical analysis was performed using SPSS version 16.0 (SPSS Inc, Chicago, IL). The results are expressed as the mean values ± standard deviation (SD). The differences between groups were tested for significance using Student's t test. Spearman method was used for correlation test. P < 0.05 was considered significant.
| RESULTS
| Expression of CD97 in three cervical cancer cell lines
Three human cervical cancer cell lines, HeLa, SiHa and C33A, were employed for the CD97 mRNA and protein expression. Figure 1A ).
SiHa cells had the strongest intensity of CD97/EGF1,2,5 mRNA (P < 0.05) ( Figure 1B ). Hela cells had the strongest intensity of CD97 EGF1,2,3,5 mRNA (P < 0.05) ( Figure 1B ). Western blot analysis revealed much stronger expression of CD97 protein in Hela and SiHa compared with almost CD97-negative C33A cell lines ( Figure 1C, D) . 
| The relationship of CD97 small isoform and migration, invasion and proliferation of human cervical cancer cells
Among three human cervical cancer cell lines investigated, SiHa cells possessed the highest number of migrated and invaded cells, which correlated with increased CD97/EGF1,2,5 mRNA (Figure 2A,B,C,D) . The invasive and migrative ability of different cervical cancer cell lines was not positively correlated with total CD97 protein level but with the extent of CD97 small isoform. The expression level of CD97 small isoform had no positive relation to proliferation capacity (by CCK8 assay) of cervical cancer cell lines. 
| The effect of CD97 small isoform on migration, invasion and proliferation of human cervical cancer cells
To verify whether the CD97 small isoform plays an important role in cervical cancer invasion, we apply siRNA for transient silencing of the CD97 small isoform gene in Hela and SiHa cells. After 48 hours of treatment with siRNA-CD97/EGF1,2,5 or a scrambled siRNA, knockdown of CD97 small isoform in Hela and SiHa cells was confirmed by RT-PCR ( Figure 3A,B) and Western blot analysis ( Figure 3C ). Furthermore, we analysed the functional effect of CD97 knockdown on cervical cancer cell movement by migration and invasion assay. Decreased capability of migration ( Figure 4A ,B) and invasion ( Figure 4C,D) was found in CD97/EGF1,2,5 RNAi cells, which had no change in cell proliferation as judged by a CCK8 assay (data not shown).
| DISCUSSION
In our previous study, we found strong immunostaining of CD97 accompanied with lymph node metastasis, advanced FIGO stage and poor prognosis, suggesting that elevated CD97 expression might be of relevance to the severity of CSCC. 12 This study further demonstrated that there was a strong correlation between the expression level of CD97 small isoform and migration as well as invasion ability of cervical cancer cell lines; reciprocally, siRNA could effectively inhibit CD97 expression and weaken the migration and invasion capacity of cervical cancer cell lines. These data suggested that CD97-mediated tumour invasion may be a pivotal contributing factor to the decreased survival associated with CD97 overexpression in cervical cancer. Our present study indicated that in three different cervical cancer cell lines, HPV16-positive SiHa cell line had the strongest intensity of CD97/EGF1,2,5 mRNA and relevant increased mobility and invasiveness as compared with HPV 18-positive HeLa cell line and HPV-negative C33A cell line. It suggested that HPV infection could increase the CD97/ EGF1,2,5 mRNA expression and different HPV subtypes might have some correlation with the degree of CD97 small isoform, which might further affect the aggressive ability of cervical cancer cells. But more experiments would be needed to prove this hypothesis. The data about correlation between CD97 and cancer aggressiveness were still limited to the cervical cancer-derived cell lines in vitro in this study. Other relevant articles about gastric cancer and hepatocellular carcinoma also used tumour cell lines. The CD97 small isoform was demonstrated to enhance metastatic capacity of gastric cancer cells in an exosome dependent fashion in vitro and in a footpad lymph node metastasis mouse model.
14 Overexpressed CD97 also promoted hepatocellular carcinoma cell migration and invasion in vitro and led to accelerated lung metastasis in an in vivo mouse model. 15 More in-depth research was considered to be needed to investigate whether data generated from tumour-derived cell lines reflects behaviour of tumours in situ. A prominent cancer characteristic is the capacity for invasion and metastasis which is associated with progression of tumours and reduced survival. Tumour invasion and metastasis comprise a series of events about direct tumour cell-cell and tumour cell-microenvironment interactions, including tumour cell separation from each other, migration into the extracellular matrix (ECM) and entry into the blood and lymph vessels. Among all G protein-coupled receptors (GPCRs), CD97 had been the most studied in the area of tumour cell migration and invasion, whose functions with respect to tumour aggressiveness and metastasis have been reported in several studies. CD97 upregulated expression was observed at the tumour "invasive front". 16, 17 The elevated expression of CD97 in carcinoma was associated with the dedifferentiation, aggressiveness, advanced stages and poor prognosis of tumours. 9, 11, [18] [19] [20] [21] Integrin α5β1 might be involved in activating matrix metalloproteinase-2 (MMP-2) to degrade the ECM 22 and promoting tumour angiogenesis. 23 Chondroitin sulphate was another component of the ECM. Since both of them were the ligands of CD97, CD97 might boost tumour cell migration and invasion through engagement with these two ligands. 24, 25 However, the underlying mechanisms about CD97 how confers an invasive phenotype of tumour have not been elucidated. CD97 has been shown to heterodimerize with the lysophosphatidic acid (LPA) receptor to amplify LPA-initiated RHO-dependent signalling and invasion in prostate cancer cells.
26 CD97 has been shown to promote gastric cancer cell proliferation and invasion in vitro through exosomemediated MAPK signalling pathway. 27 Furthermore, CD97 promoted tumour aggressiveness through the traditional G protein-coupled receptor-mediated signalling in hepatocellular carcinoma. 15 The mechanisms how CD97 expression is regulated also remain unclear. Significant decreased invasiveness of tumour cell and reduced expression of CD97 were observed as a result of the Wilms' tumour 1 (WT-1) gene silencing in malignant gliomas, suggesting the overexpression of CD97 mediated by WT-1 might promote cellular invasiveness. 28 A link between upregulation of CD97 and downregulation of tumour suppressor miR-126 was found in the breast cancer cell line MDA-MB-231, which provided mechanistic insight into the role of miR-126 in inhibiting cancer progression with CD97 as a direct target. 29 Accumulating evidence of the involvement of CD97 in tumorigenesis has laid a solid foundation for further studies as potential therapeutic target. This study has indicated that the CD97 small isoform in particular may be a target. Future research is necessary to illuminate the role and mechanism of CD97 in cervical cancer invasion and metastasis using in vivo models. 
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